Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

The presence of inflammation on liver biopsy is associated with the development of advanced fibrosis in NASH. The presence of acinar inflammation is essential for the histological diagnosis of ...

Driven by rising levels of obesity, NASH causes fibrosis and swelling in the liver and has become a leading concern in healthcare as increasing numbers of people with the condition advance to ...

Barker et al [43] found improvement in steatosis, lobular inflammation, and portal/lobular fibrosis in the majority of the 19 patients studied. In addition, histopathologic criteria for NASH were ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

The test is not for use in the diagnosis of NASH or for the staging of fibrosis. Please contact Siemens Healthineers directly for availability. The Enhanced Liver Fibrosis (ELF TM) Test is a non ...

NASH is a progressive form of liver disease that carries a risk of progressive fibrosis, cirrhosis and end-stage liver disease. Worldwide, the prevalence of NASH in the general population is 3–5%.

One such disease, nonalcoholic steatohepatitis (NASH), is characterized by dysregulated metabolism, inflammation and fibrosis. According to Axcella’s Chief Medical Officer and Executive Vice ...